Related Experiment Videos
Acetylator polymorphism in human colorectal carcinoma.
J M Ladero1, J F González, J Benítez
1Department of Medicine, Complutense University, Madrid, Spain.
Cancer Research
|April 15, 1991
Summary
This study found no link between slow acetylator phenotype and colorectal cancer risk. Acetylator polymorphism does not appear to be a genetic factor in developing this common cancer.
Area of Science:
- Pharmacogenetics
- Gastroenterology
- Oncology
Background:
- The acetylator phenotype, influenced by genetic variations, affects drug metabolism.
- Colorectal carcinoma is a significant global health concern with complex etiology.
- Investigating genetic predispositions like acetylator status is crucial for understanding cancer risk.
Purpose of the Study:
- To investigate the association between acetylator phenotype and the risk of developing colorectal carcinoma.
- To determine if genetic variations in drug metabolism influence colorectal cancer susceptibility.
Main Methods:
- Acetylator phenotype was assessed using sulfamethazine.
- The study included 109 patients with colorectal carcinoma and 96 age-matched controls.
- Statistical analysis, including chi-squared test, was employed to compare phenotype distributions.
Main Results:
- No significant difference was observed in the distribution of slow acetylator phenotypes between colorectal cancer patients (55%) and controls (58.3%).
- Subgroup analyses (sex, surgical status, tumor location) also revealed no significant associations.
- The observed differences were not statistically significant (chi 2 = 0.11).
Conclusions:
- Acetylator polymorphism is not identified as a genetic risk factor for colorectal carcinoma in the studied population.
- These findings suggest that variations in drug metabolism related to acetylation are unlikely to play a major role in colorectal cancer development.